Grifols to build new R&D hub to work on immune disorders

28 April 2021

Spanish plasma specialist Grifols (GRF: MC) is to establish a global R&D hub in Andorra, focused on the human immune system and the potential for novel immune therapies.

The planned facility, the Pyrenees Immunology Research Center (PYIRC), will be tasked with investigating treatments for conditions including autoimmunity disorders, cancer and emerging infectious diseases.

Developed with the participation of the Andorran authorities, the center is due to be completed in 2023, and will be one of only a few in Europe dedicated to immunology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK